12.02.14
Eisai has opened a new potent packaging facility at its EMEA Knowledge Centre in Hatfield, investing £8 million. The facility will handle the packaging of its investigational compound lenvatinib for the treatment of advanced thyroid cancer.
The 2,900m2 facility has hybrid packaging lines designed for highly potent, difficult-to-handle compounds, expanding the current Hatfield site by nearly 40%. The investment represents Eisai's long-term global business structure to make the UK a key hub. The Hatfield site is the company's EMEA headquarters and serves as a global supply center of excellence for key products.
Eisai has invested more than £150 million in the Hatfield site, which has more than 500 employees and the capacity to produce as many as 450 million tablets in 10 million packs each year. The new packaging facility will increase employment at the site by 10%.
"We are extremely proud of this new development at our EMEA Knowledge Centre. The UK is an ideal location for advanced manufacturing. We are committed to the life sciences industry in this country and it will continue to play a pivotal role in our commercial growth strategy," said Haruo Naito, chief executive officer of Eisai. "This new high tech facility enhances our capability as a center of packaging excellence for our growing product range."
Lenvatinib was granted orphan drug designation for follicular and papillary thyroid cancer by the European Commission and regulatory submissions have been made in the EU, U.S. and Japan.
The 2,900m2 facility has hybrid packaging lines designed for highly potent, difficult-to-handle compounds, expanding the current Hatfield site by nearly 40%. The investment represents Eisai's long-term global business structure to make the UK a key hub. The Hatfield site is the company's EMEA headquarters and serves as a global supply center of excellence for key products.
Eisai has invested more than £150 million in the Hatfield site, which has more than 500 employees and the capacity to produce as many as 450 million tablets in 10 million packs each year. The new packaging facility will increase employment at the site by 10%.
"We are extremely proud of this new development at our EMEA Knowledge Centre. The UK is an ideal location for advanced manufacturing. We are committed to the life sciences industry in this country and it will continue to play a pivotal role in our commercial growth strategy," said Haruo Naito, chief executive officer of Eisai. "This new high tech facility enhances our capability as a center of packaging excellence for our growing product range."
Lenvatinib was granted orphan drug designation for follicular and papillary thyroid cancer by the European Commission and regulatory submissions have been made in the EU, U.S. and Japan.